Traders should monitor for FDA meeting confirmation and feedback, which could serve as a near-term catalyst. Positive regulatory engagement may revalue the stock given the small $13M market cap and unmet need in HFrEF. Watch for enrollment updates in ongoing trials and potential partnership interest.
Price Chart
Executive Summary
BioCardia announced it has submitted clinical data to the FDA and requested a meeting to discuss an accelerated approval pathway for its CardiAMP System in ischemic chronic heart failure. The company highlighted positive subgroup results showing a 47% relative risk reduction in cardiac death and 37% reduction in non-fatal major adverse cardiac events.
Key Facts
- BioCardia submitted CardiAMP HF clinical study data to the FDA and requested a meeting to discuss accelerated approval for ischemic HFrEF.
- The meeting will be conducted under the FDA's Breakthrough Therapy designation.
- In a subgroup of patients with elevated biomarkers of heart stress, treatment showed a 47% relative risk reduction in all-cause cardiac death and 37% reduction in non-fatal MACE over two years.
- Quality of life improvements were statistically significant (p=0.04).
- Latest results were presented at the THT 2026 Annual Meeting.
Financial Impact
No direct financial impact disclosed; potential future revenue from accelerated approval pathway for a novel cell therapy in a high-need cardiovascular indication.
Risk Factors
- FDA may not agree to accelerated approval or may require additional data.
- Subgroup results may not translate to broader population.
- Company has limited liquidity, per forward-looking statements.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001437749-26-010967 |
| Exhibit: ex_940999.htm | 0001437749-26-010967 |
| Document: 0001437749-26-010967-index-headers.html | 0001437749-26-010967 |
| Document: 0001437749-26-010967-index.html | 0001437749-26-010967 |
| Document: 0001437749-26-010967.txt | 0001437749-26-010967 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 7d ago | 8-K | $0.8975 $1.04 | ▲ +15.88% | ▲ +15.54% | $0.9000 (+0.28%) |
Oct 19, 2026 7d ago | Press Release | $0.9000 $1.04 | ▲ +15.56% | ▲ +15.22% | $0.9000 (−0.00%) |
Oct 7, 2026 19d ago | 8-K | $1.09 $1.06 | ▼ −2.75% | ▼ −2.33% | $0.9000 (−17.43%) |
Oct 1, 2026 25d ago | 8-K | $1.02 $1.04 | ▲ +1.96% | ▲ +1.22% | $0.9000 (−11.76%) |
Oct 1, 2026 25d ago | Press Release | $1.02 $1.04 | ▲ +1.96% | ▲ +1.22% | $0.9000 (−11.76%) |
Sep 23, 2026 4w ago | 8-K | $1.05 $1.07 | ▲ +1.90% | ▲ +1.99% | $0.9000 (−14.29%) |
Sep 23, 2026 4w ago | Press Release | $1.05 $1.07 | ▲ +1.90% | ▲ +1.99% | $0.9000 (−14.29%) |
Sep 10, 2026 6w ago | 8-K | $1.10 $1.08 | ▼ −1.82% | ▼ −2.67% | $0.9000 (−18.18%) |
Aug 24, 2026 9w ago | 8-K | $1.06 $1.13 | ▲ +6.60% | ▲ +6.28% | $0.9000 (−15.09%) |
Aug 5, 2026 11w ago | Press Release | $0.9500 $0.9496 | ▼ −0.04% | ▲ +0.12% | $0.9000 (−5.26%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers